Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy, Biologic therapy.

Washington University School of Medicine, St. Louis, Missouri, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:St. Louis, Missouri
Treatments:Chemotherapy, Biologic therapyHospital:Washington University School of Medicine
Drugs:Journal:Link
Date:Sep 2010

Description:

Patients:
This phase 2 study involved 79 men with castrate-resistant prostate cancer. The median age of the group was 69 years.

Treatment:
Patients in this study were given a combination of two chemotherapy agents, docetaxel and estramustine, and a biologic therapy agent bevacizumab, which is an antibody the blocks a protein involved in cancer cell growth.

Toxicities:
There were 3 deaths related to treatment reported in this study. Causes included infection and thrombosis. Grade 3 and 4 neutropenia, leukopenia, fatigue, and pain were also reported.

Results:
The reported median progression-free survival in this study was 8 months. The median overall survival was 24 months.

Support:
This study was partially supported by Sanofi-Aventis and Genentech, makers of docetaxel and bevacizumab, respectively.

Correspondence: Dr. Joel Picus; email: [email protected]



Back